-
Why This Seelos Therapeutics Analyst Is Turning Bullish On Potential Trial Results
Monday, September 27, 2021 - 3:11pm | 274Read More...Part A results from the trial of Seelos Therapeutics Inc’s (NASDAQ: SEEL) intranasal ketamine product candidate, SLS-002, and the clarity around the timing of the Part B data release call for a change in recommendation, according to Roth Capital. The Seelos Therapeutics Analyst: Jonathan...
-
Inovio Analyst: COVID-19 Competition Could Be Too Great
Tuesday, November 17, 2020 - 6:41pm | 447Read More...Inovio Pharmaceuticals Inc (NASDAQ: INO) reported Monday the lifting of the FDA-imposed partial clinical hold on the start of the Phase 2 study of INO-4800, its DNA coronavirus vaccine candidate. The Inovio Analyst: Roth Capital Partners analyst Jonathan Aschoff downgraded Inovio...
-
Roth Downgrades Inovio On Valuation Despite Positive MERS Vaccine Data
Thursday, April 30, 2020 - 1:45pm | 290Read More...Although Inovio Pharmaceuticals Inc (NASDAQ: INO) reported positive interim results from Phase 1 and 2a of its MERS vaccine, the valuation of the stock already reflects this, especially given the increase in share count since the end of 2019, according to Roth Capital Partners. The Inovio Analyst...
-
Exparel Concerns Weigh On Pacira Pharma, Brean Moves To Sidelines
Friday, July 1, 2016 - 9:20am | 412Read More...Brean Capital has downgraded Pacira Pharmaceuticals Inc (NASDAQ: PCRX) to Hold from Buy after the FDA said it is evaluating adverse event reports of local anesthetic systemic toxicity (LAST) with company's drug Exparel. "We are downgrading Pacirato Hold from Buy for what we believe will amount to...
-
If Medivation Is Sold, Brean Thinks It'll Be For Far More Than Sanofi's Bid
Friday, May 6, 2016 - 10:29am | 267Read More...Medivation Inc (NASDAQ: MDVN) reported its U.S. and ex-U.S. Xtandi sales for 1Q16 in line with the consensus. Brean Capital’s Jonathan Aschoff maintains a Buy rating on the company, with a price target of $61. Xtandi Outlook Growth in the underlying demand for Xtandi has continued, rising...
-
Brean Initiates Alder BioPharma At Buy, $45 Price Target
Wednesday, April 20, 2016 - 9:46am | 214Read More...Alder Biopharmaceuticals Inc (NASDAQ: ALDR) reported positive Phase 2b results for its lead product candidate ALD403, a novel monoclonal antibody in development for migraine prevention. Brean Capital’s Jonathan Aschoff initiated coverage of the company with a Buy rating and a price target...
-
Brean Initiates SCYNEXIS With Buy Rating, $16 Price Target
Monday, March 28, 2016 - 8:50am | 288Read More...Brean Capital’s Jonathan Aschoff initiated coverage of SCYNEXIS Inc (NASDAQ: SCYX) with a Buy rating and a price target of $16, citing prospects of the company’s leading novel antifungal drug. SCY-078 is being developed as an intravenous as well as an oral agent for the treatment of...
-
Focalin Sales May Be Weak...But It Won't Hurt This Stock
Saturday, October 10, 2015 - 12:45pm | 361Read More...IntelliPharmaCeutics Intl Inc (USA) (NASDAQ: IPCI) shares are down 48 percent year-to-date, plunging in August, and continuing a downward trend in September. Brean Capital’s Jonathan Aschoff maintained a Buy rating on the company, with a price target of $8. Although Focalin sales in...
-
Merrimack Pharma Could Have FDA Approval Coming; These Analysts Are Buying
Tuesday, October 6, 2015 - 10:38am | 264Read More...Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) has seen a 20.88 percent decline in its share price over the last six months, from a high of $13.67 on April 23. Brean Capital’s Jonathan Aschoff has maintained a Buy rating on the company, with a price target of $16. Aschoff believes...
-
Tetraphase's Stock Just Lost 80%, You Should Flush It...Right?
Wednesday, September 9, 2015 - 2:22pm | 780Read More...Shares of Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH) plunged nearly 80 percent on Wednesday, trading as low as $9.00 per share. The massive selloff is attributed to the company failing to meet the primary endpoint of statistical non-inferiority for IGNITE2 compared to levofloxacin. Here is a...
-
Alexion Pharmaceuticals Is Still A Buy, Despite Rx Kanuma's Review-Date Delay
Friday, September 4, 2015 - 3:27pm | 383Read More...In a report issued Friday, Brean Capital analyst Jonathan Aschoff looks into Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) and, after some minor model adjustments, reiterated a Buy rating and $221.00 target price on the stock. The slight tweak in the firm’s financial model was triggered by...
-
Biotech Pair Trade? Brean Weighs In On Keryx Biopharma And Rockwell Medical
Tuesday, June 23, 2015 - 12:07pm | 414Read More...On June 22, Brean Capital analyst Jonathan Aschoff weighed in on Keryx Biopharmaceuticals Inc (NASDAQ: KERX) and Rockwell Medical Inc (NASDAQ: RMTI) to provide commentary on both companies’ dialysis drugs. Keryx Biopharmaceuticals focuses its attention on providing care for patients with...
-
Cantor, Brean Capital Like Celldex Therapeutics Following Positive Data For Brain Tumor Therapy
Monday, June 1, 2015 - 2:13pm | 526Read More...Celldex Therapeutics, Inc. (NASDAQ: CLDX) shares were up more than 10 percent in pre-market trading today after the biopharmaceutical company released positive trial results from the Rintega study. The study successfully reached its primary endpoint of progression-free survival at six months in...
-
Is Keryx Still A Good Buy After Weak Prescription Data?
Tuesday, May 5, 2015 - 12:45pm | 848Read More...Keryx Biopharmaceuticals (NASDAQ: KERX) reported first quarter 2015 earnings on May 4. All eyes were on Auryxia, Keryx’s lead product for patients with chronic kidney disease on dialysis. Keryx posted total revenue of $1.175 million, including 1,218 prescriptions filled for Auryxia in the...
-
Analyst: Chimerix Govt. Smallpox Pact Worth Up To $435 Million
Thursday, April 16, 2015 - 7:39am | 199Read More...Chimerix Inc (NASDAQ: CMRX)'s proposed government contract to produce up to 1.7 million doses of a treatment for smallpox could be worth up to $435 million, an analyst said Wednesday. The company was awarded the sole-source, five-year contract Monday, although it would formally receive it until...
